Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide, but there are few effective treatments. Aberrant microRNA (miRNA) biogenesis is correlated with HCC development. We previously demonstrated that peptidyl-prolyl cistrans isomerase NIMA-interacting 1 (Pin1) participates in miRNA biogenesis and is a potential HCC treatment target. However, how Pin1 modulates miRNA biogenesis remains obscure. Here, we present in vivo evidence that Pin1 overexpression is directly linked to the development of HCC. Administration with the Pin1 inhibitor (API-1), a specific small molecule targeting Pin1 peptidyl-prolyl isomerase domain and inhibiting Pin1 cis-trans isomerizing activity, suppresses in vitro cell proliferation and migration of HCC cells. But API-1-induced Pin1 inhibition is insensitive to HCC cells with low Pin1 expression and/or low exportin-5 (XPO5) phosphorylation. Mechanistically, Pin1 recognizes and isomerizes the phosphorylated serine-proline motif of phosphorylated XPO5 and passivates phosphorylated XPO5. Pin1 inhibition by API-1 maintains the active conformation of phosphorylated XPO5 and restores XPO5-driven precursor miRNA nuclear-to-cytoplasm export, activating anticancer miRNA biogenesis and leading to both in vitro HCC suppression and HCC suppression in xenograft mice. Conclusion: Experimental evidence suggests that Pin1 inhibition by API-1 up-regulates miRNA biogenesis by retaining active XPO5 conformation and suppresses HCC development, revealing the mechanism of Pin1-mediated miRNA biogenesis and unequivocally supporting API-1 as a drug candidate for HCC therapy, especially for Pin1-overexpressing, extracellular signal-regulated kinase-activated HCC. (HEPATOLOGY 2018; 68:547-560).
H epatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide and represents the third leading cause of cancer death.
(1) Alcohol consumption and hepatitis B virus or hepatitis C virus infection are the major risk factors for the genesis and development of HCC. (2) Although several treatment approaches have been developed, including curative and pharmacological therapies, (3) their efficacies are not satisfactory. Curative therapy is only effective for patients treated at an early stage. (4) Pharmacological therapy using sorafenib, a standard medical treatment approved by the Food and Drug Administration to treat advanced HCC by blocking the Ras-Raf-mitogen-activated protein kinase kinase Abbreviations: API-1, Pin1 inhibitor; DMSO, dimethyl sulfoxide; ERK, extracellular signal-regulated kinase; GST, glutathione S-transferase; HCC, hepatocellular carcinoma; IC50, 50% inhibition concentration; MEK, mitogen-activated protein kinase kinase; miRNA, microRNA; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PDB ID, Protein Data Bank identifier; Pi interaction, p interaction; Pin1, peptidylprolyl cis-trans isomerase NIMA-interacting 1; PPIase, peptidyl-prolyl isomerase; pre-miRNA, precursor miRNA; pXPO5, phosphorylated XPO5; shPin, short hairpin Pin; wt, wild-type; XPO5, exportin-5.
(MEK)-mitogen-activated protein kinase pathway, prolongs overall survival but fails to achieve adequate rates of response or to stabilize the disease. (5, 6) Thus, novel approaches, especially targeted therapy, are urgently needed for HCC treatment.
MicroRNAs (miRNAs) are a class of small noncoding RNAs that regulate gene expression by repressing protein translation or destabilizing target mRNAs. (7, 8) miRNAs, such as miR-122 and let-7a, either as prognostic or as diagnostic markers, are significant regulators of gene expression and globally down-regulated in many tumors, including HCC. (9, 10) Aberrant miRNA expression promotes HCC development and metastasis. (11) Importantly, reduced miRNA expression in liver cancer is attributed to defects in miRNA biogenesis. (12) Therefore, establishing how to restore normal miRNA biogenesis is essential for HCC treatment.
miRNA biogenesis is a multiple-step process: (1) the miRNA gene is transcribed into primary miRNA by RNA polymerase II, (2) primary miRNA is cleaved to precursor miRNA (pre-miRNA) by Drosha, (3) premiRNA is exported from the nucleus to the cytoplasm by exportin-5 (XPO5), and (4) pre-miRNA is processed into mature miRNA by Dicer and loaded onto the Argonaute protein to produce a functional RNAinduced silencing complex. (13) In this process, the nucleus-to-cytoplasm export of pre-miRNA by XPO5 is a rate-limiting step. (14) Recently, we demonstrated that the peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (Pin1) impairs XPO5 activity in HCC following the phosphorylation of XPO5 by extracellular signal-regulated kinase (ERK) at T345/S416/S497. Thus, mature miRNA biogenesis is reduced. (15) Although the precise mechanisms regarding how Pin1 regulates miRNA biogenesis and the consequences of Pin1 inhibition are unclear, these findings shed light on potential new HCC therapies targeting Pin1 to restore miRNA biogenesis.
Pin1 contains a WW domain for substrate recognition and a catalytic peptidyl-prolyl isomerase (PPIase) domain with a flexible loop between them. Binding of the phosphorylated serine/threonine-proline motif of the substrate to the WW domain induces Pin1 to catalyze cis-trans isomerization and alter the structure and function of the substrates. (16) Pin1 is a key regulator in multiple physiological processes, including RNA processing and cell cycle progression, and is widely overexpressed and/or overactivated in multiple cancers, including HCC. (17) Thus, Pin1 is an attractive target for HCC therapy.
The first discovered Pin1 inhibitor is juglone, which irreversibly inhibits Pin1 activity by binding covalently to the C113 residue. (18) Epigallocatechin gallate interferes with Pin1 recognition of its substrates and blocks cis-trans isomerization by reversibly binding to both the WW domain and the PPIase domain. (19) However, these Pin1 inhibitors still lack the required potency and specificity. (20) Recently, it was reported that all-trans retinoic acid directly binds to and degrades the active form of Pin1, suppressing acute promyelocytic leukemia and breast cancer, (21, 22) although the extensive toxicity caused by nuclear retinoic acid receptors limits its clinical application. (23) Therefore, there is still a great demand to develop novel Pin1 inhibitors for targeted therapy and mechanism studies; this need prompted us to screen more potent and specific Pin1 inhibitors that restore XPO5 function for HCC treatment. 
Materials and Methods

COMPUTER-AIDED
PPIase ACTIVITY ASSAY
A typical PPIase activity assay involves glutathione S-transferase (GST)-Pin1 (80 nmol/L), achymotrypsin (6 mg/mL; Sigma), Suc-AEPFpNA (50 lmol/L; Abcam), and test samples for reaction. Sample and GST-Pin1 protein were preincubated for 10 minutes, and the mixture was added to the reaction buffer containing achymotrypsin. The reaction was initiated by the addition of the Suc-AEPF-pNA, and the reaction progress was monitored at 390 nm on a Thermo Scientific Varioskan Flash Multimode Reader at 48C for 180 seconds.
TUMOR XENOGRAFT EXPERIMENT
Animal studies were conducted under the approval of the Experimental Animal Management Committee of Sichuan University. HCC cells were harvested during the exponential-growth phase and washed with serum-free medium, followed by resuspension in Matrigel (Corning) at a concentration of 3 3 10 7 /mL. Then, 100 lL of cell suspension was injected into female BALB/c mice (5 weeks old) subcutaneously. After the tumor sizes reached 150-200 mm 3 , all mice were randomized into two groups (six mice per group) and intravenously injected with API-1 (5 or 10 mg/kg/ 2 days) or vehicle, which was prepared in normal saline solution with 5% dimethyl sulfoxide (DMSO). Tumor growth was recorded every 3 days, and the tumor volume was calculated as ab 2 3 0.52 (a, long diameter; b, short diameter).
STATISTICAL ANALYSIS
Statistical analyses of differences were performed using the Student t test in GraphPad Prism 6.0. P < 0.05 was considered statistically significant.
See Supporting Information for details on other materials and methods. (Fig. 1A) . Furthermore, the Pin1 level in advanced-stage HCC (n 5 51) was higher than that in early-stage HCC (n 5 88), implying that Pin1 played an important role during HCC development (Supporting Fig. S1A ). Western blotting analysis also demonstrated Pin1 overexpression in HCC tumors ( Fig. 1B; Supporting Fig. S1B ). Furthermore, we collected human normal liver, cirrhosis, and HCC tissues. Immunohistochemical analysis showed that Pin1 was remarkably up-regulated in HCC comparing normal liver and cirrhosis tissues (Supporting Fig. S1C ), indicating that Pin1 might be a specific regulator in HCC.
Results
Pin1
A WW domain for recognizing substrate and a PPIase domain for catalyzing cis/trans isomerization of phosphorylated serine/threonine-proline motif constitute the main structure of Pin1 (Fig. 1C) . (24) Given the abundant crystal structures of Pin1 active sites in the PDB, we employed computer-aided highthroughput virtual screening to discover novel Pin1 inhibitors. To establish the virtual screening model, crystal structures of the Pin1 PPIase domain and WW domain were evaluated, and two structures (PDB ID, 3IKD and 3I6C) (25, 26) of the PPIase domain were identified as more reliable than others for molecular docking (Supporting Fig. S1D ). Highthroughput screening of a 13,541-compound library, including a commercially available library and a selfbuilt library, were performed by GOLD molecular docking (27) to screen the structure-matching compounds (Supporting Fig. S1E ). API-1 was one of the screened-out lead compounds, with high scores for both structure models (Fig. 1D) . These compounds were then used for the in vitro PPIase activity assay, which uses GST-Pin1 as an isomerase and is suitable for measuring biological inhibitory activity against Pin1 (Supporting Fig. S1F ).
Among the candidates tested for biological activity, the chemical synthetic small molecule API-1, which had a 6-O-benzylguanine skeleton (Supporting Fig.  S1G ), showed potent Pin1 inhibition with a 50% inhibition concentration (IC50) of 72.3 nM, which was >100-fold less than that of juglone (7.68 lM), the first discovered Pin1 inhibitor and the positive control for this study ( Fig. 1E; Supporting Fig. S1H ). API-1 showed no effect on a-chymotrypsin activity, confirming that the activity of API-1 against Pin1 isomerase was not a false-positive result (Supporting Fig. S1I ). Importantly, API-1 showed remarkable selectivity toward Pin1 over other peptidyl-prolyl cis-trans isomerases, including Pin4, FKBP12, and cyclophilin A (Fig. 1F) . Therefore, these in vitro data showed that the enzymatic activity of Pin1, which was overexpressed in HCC, was potently and specifically inhibited by a 6-O-benzylguanine derivative, API-1.
Pin1 INHIBITOR API-1 BINDS THE PPIase DOMAIN OF Pin1 THROUGH KEY RESIDUES
To predict the binding pattern of Pin1 and API-1, several in silico calculations were performed. Flexible docking results indicated that API-1 interacted with amino acid residues K63, R69, C113, M130, Q131, and H157 of Pin1 and docked into the groove of the PPIase domain ( Fig. 2A) . To verify the stability of API-1 binding to Pin1, we next performed 30-ns molecular dynamic simulations on the docking model of the API-1/wild-type Pin1 (wtPin1) complex. Compared with the initial system, the conformations of API-1 and amino acid residues K63, R69, C113, M130, Q131, and H157 were not remarkably changed after 30-ns simulations (Fig. 2B) . The low root-meansquare deviation fluctuations proved that the wtPin1/ API-1 system was a well-behaved system without large conformational changes (Fig. 2C) . However, the K63A Pin1/API-1 system exhibited conformational change during this simulation, suggesting that K63 was a key amino acid residue for API-1 binding (Fig. 2C) .
To verify Pin1-API-1 interaction from the in silico calculations, we subsequently characterized the in vitro interaction between Pin1 and API-1. wtPin1 was expressed and purified, and the inhibition of its enzymatic activity by API-1 was verified (Supporting Fig. S2A ). In the thermal shift assay, API-1 increased the thermal stability of wtPin1, with a temperature shift of 1.478C (Fig. 2D) . Additionally, isothermal titration calorimetric measurements showed strong binding affinity with a dissociation constant of 2.62 lM (Fig. 2E) . Furthermore, API-1 incubation increased Pin1 stability upon subtilisin A-mediated proteolytic cleavage (Supporting Fig. S2B ). But API-1 incubation did not stabilize cyclophilin A (Supporting Fig. S2B ), which is inactive to API-1 (Fig. 1F) , suggesting that API-1 was not an inhibitor of subtilisin A. These data indicated a direct interaction between Pin1 and API-1.
To further examine the key binding residues, molecular mechanics-generalized Born and surface area energy decomposition was performed on the wtPin1/ API-1 complex to calculate the contribution of each residue to the total binding energy. K63 and R69, which had high residue energy contributions, interacted primarily with API-1, whereas the remaining total binding energy was mostly dispersed by R68, C113, Q131, and H157 (Fig. 2F, top) . To verify this presumption, K63A, R69A, C113A, M130A, Q131A, and H157A Pin1 mutants were constructed; and assays for PPIase activity and thermal shift were performed after API-1 incubation. These site-directed mutations were potential residues involved in the noncovalent interaction between receptor and ligand during flexible docking ( Fig. 2A) . K63A and R69A mutants strongly decreased the inhibitory effect of API-1 by >50%, and C113A, Q131A, and H157A mutants exhibited a moderate effect, indicating that these residues in the PPIase domain were responsible for the binding of API-1 to Pin1 isomerase ( Fig. 2F,  bottom; Supporting Fig. S2C ). Additionally, only small thermal shifts were observed in K63A and R69A mutants treated with API-1 (Supporting Fig. S2D,E) , whereas C113A and M130A mutants showed larger shifts of 0.748C and 1.428C, respectively (Supporting Fig. S2F,G) . Moreover, the dissociation constants of Pin1 K63A and R69A to API-1 measured by isothermal titration calorimetric experiments using Pin1 K63A, R69A, M130A, and Q131A as receptor were increased (Supporting Table S1 ), highlighting the pivotal role of K63 and R69 residues for the binding to API-1.
Pin1 INHIBITION SUPPRESSES HCC CELL PROLIFERATION AND MIGRATION IN A Pin1 EXPRESSION/XPO5 PHOSPHORYLATION-DEPENDENT MANNER
With the Pin1 inhibitor API-1 in hand, we subsequently assessed its activity in HCC cells. In the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, API-1 had stronger antiproliferative activity than juglone and its performance was done in a dose-dependent and time-dependent manner ( Fig. 3A; Supporting Fig. S3A ). API-1 also inhibited colony formation in SK-Hep-1 cells (Supporting Fig. S3B ). To evaluate the specificity of API-1, we analyzed the levels of Pin1, phosphorylated XPO5 (pXPO5), XPO5, phosphorylated ERK, and ERK in several native HCC cells by western blotting and conducted MTT assays in these cells. API-1 obviously inhibited SK-Hep-1, SNU-423, and Hep3B cell proliferation with low IC50 values; but Huh7 and SMMC-7721 cells were insensitive to API-1 treatment ( Fig. 3B, left ; Supporting Table S2 ). The results of western blotting showed that SK-Hep-1, SNU-423, and Hep3B cells had high levels of both Pin1 expression and XPO5 phosphorylation, while Pin1 expression and/or XPO5 phosphorylation were at low levels in Huh7 and SMMC-7721 cells (Fig. 3B, right) . Thus, we speculated that API-1 activity in HCC might be dependent on both Pin1 expression and XPO5 phosphorylation.
To test this hypothesis, we established stable short hairpin Pin1 (shPin1)-knockdown SK-Hep-1 cells (SK-Hep-1-shPin1; Fig. 3C, right) . As expected, SK-Hep-1-shPin1 cells were less sensitive to API-1 treatment than the scrambled short hairpin RNA-transfected SK-Hep-1 cells (SK-Hep-1-CTL; Fig. 3C, left) . Intriguingly, API-1 caused distinct changes to cellular morphology in SK-Hep-1-CTL cells, whereas very little change was observed in SK-Hep-1-shPin1 cells (Supporting Fig. S3C ). Because Pin1 function in miRNA biogenesis requires the presence of pXPO5, to evaluate the influence of pXPO5, we transiently transfected SK-Hep-1-CTL and SK-Hep-1-shPin1 cells with constitutively active MEK (MEKDD) plasmid (MEKDD activates ERK, which is responsible for XPO5 phosphorylation (16) ). Increased pXPO5 level potentiated API-1 activity in SK-Hep-1-CTL cells (Supporting Fig. S3D,E) . However, this potential vanished in SK-Hep-1-shPin1 cells (Supporting Fig. S3D,  F) . These data indicated that (1) when Pin1 was expressed at a low level, API-1 was insensitive, no matter whether XPO5 was highly phosphorylated, because API-1 is a specific Pin1 inhibitor (Fig. 1F) ; (2) in cells with a high level of Pin1, pXPO5 is required to mediate API-1 activity. To further identify this conclusion, we overexpressed MEKDD in Huh7 cells (Huh7-MEKDD) to increase the pXPO5 level (Fig. 3D, right). API-1 had improved activity in Huh7-MEKDD comparing empty vector-transfected Huh7 cells (Huh7-CTL; Fig. 3D, left) . In addition, Pin1 overexpression increased the API-1 response in both Huh-7-CTL and Huh-7-MEKDD cells (Supporting Fig.  S3G ), and Pin1-knockdown made these cells insensitive to API-1 treatment (Supporting Fig. S3H, left) . These data further demonstrated that the antiproliferative effect of API-1 was mediated by Pin1 expression and XPO5 phosphorylation.
To test whether API-1 affects XPO5 phosphorylation in a Pin1-independent manner, we knocked down Pin1 in Huh-7-CTL and Huh-7-MEKDD cells. Upon API-1 incubation, the level of XPO5 phosphorylation was unchanged (Supporting Fig. S3H, right) , indicating that API-1 had no effect on XPO5 phosphorylation. The results of flow cytometry suggested that the reduced cell proliferation after API-1 treatment was due to cell cycle arrest ( Fig. 3E; Supporting Fig.  S3I ) rather than apoptosis (Supporting Fig. S3J,K) .
To identify the effect of API-1 on cell migration, transwell migration and wound healing assays were performed in SK-Hep-1-CTL and SK-Hep-1-shPin1 cells. API-1 decreased SK-Hep-1-CTL cell migration compared to SK-Hep-1-shPin1 cells in the transwell migration assay (Fig. 3F) . Similar to the wound healing assay, the mobility of SK-Hep-1-CTL cells was significantly suppressed by API-1, whereas cell migration in shPin1 cells was not inhibited (Fig. 3G) , indicating that API-1 antimigration activity was dependent on Pin1 expression. These findings indicated that API-1 prevented HCC proliferation and migration by targeting Pin1 isomerase.
Pin1 INHIBITION MAINTAINS THE ACTIVE pXPO5 CONFORMATION, RESCUES THE PRE-miRNA LOADING OF pXPO5, AND INCREASES MATURE miRNA BIOGENESIS
We previously reported that XPO5 phosphorylated by ERK was subjected to Pin1, leading to downregulation of miRNA expression, indicating Pin1 involvement in miRNA biogenesis. (16) However, the precise mechanism underlying Pin1 function still keeps obscure. Given that API-1 exhibited its antitumor effect in a Pin1-dependent and pXPO5-dependent manner, we speculated that API-1 was a regulator of miRNA biogenesis. Next, we used API-1 as a molecular tool to investigate the molecular mechanism of Pin1 on miRNA expression.
We have demonstrated an interaction between Pin1 and API-1 (Fig. 2) . To explore the downstream mechanism, two XPO5 polypeptides (494-499 residues) with phosphorylated (SVFpSPS-pNa) or nonphosphorylated (SVFSPS-pNa) S497 were customized. The p-nitroaniline label added at the C terminus is subjected to cleavage by a-chymotrypsin after Pin1-induced cis/trans isomerization of pXPO5, and released free p-nitroaniline is a Pin1 activity reporter in the in vitro isomerization assay. Compared with SVFSPS-pNa, the phosphorylated peptide SVFpSPSpNa was more sensitive to isomerization by Pin1, verifying that this isomerization relied on serine phosphorylation ( Fig. 4A; Supporting Fig. S4A ). Moreover, SVFpSPS-pNa isomerization was potently inhibited by API-1 when compared to the positive control juglone ( Fig. 4A; Supporting Fig. S4B ). These results suggested that Pin1 recognized and catalyzed the cis/trans isomerization of serine-phosphorylated XPO5. To further investigate whether Pin1 inhibition blocked conformational changes in pXPO5, partial proteolytic cleavage assays were performed. The XPO5 protein used in partial proteolytic cleavage assays was highly phosphorylated (Supporting Fig. S4C ). Subtilisin A degraded pXPO5 more effectively when incubated with GST (lane 4) than when incubated with GST-Pin1 (lane 5), suggesting that Pin1 changed protein conformation of pXPO5 (Fig. 4B) . Moreover, Pin1 inhibition by API-1 enhanced pXPO5 degradation (lane 6), demonstrating that API-1 potently inhibited Pin1-mediated conformational change to pXPO5. Because the GST pull-down assay and coimmunoprecipitation assay showed that API-1 had no effect on the interaction of Pin1 with pXPO5 (Supporting Fig. S4D,E) , so it was proposed that API-1 inhibited Pin1 catalytic activity without influencing the Pin1-pXPO5 interaction, preventing pXPO5 from isomerization and retaining pXPO5 in an active conformation.
To gain insight into the effect of Pin1 on pXPO5 cellular distribution and function, confocal imaging and RNA solution hybridization assays were performed. In HCC cells, pXPO5 was retained in the nucleus, but Pin1 inhibition by API-1 restored the nucleus-to-cytoplasm export of pXPO5 (Fig. 4C ). In accordance with pXPO5, pre-miRNA showed a preference for nuclear localization in basal conditions (Fig.  4D) . Upon Pin1 inhibition by API-1, a robust increase in pre-miRNA export from the nucleus to the PU, LI, ET AL. cytoplasm was observed (Fig. 4D) . Consequently, the biogenesis of mature miRNAs (miR-122, let-7a, miR29b, and miR-146a) was up-regulated after API-1 treatment in SK-Hep-1 cells (Fig. 4D,E) . Importantly, Pin1 inhibition by API-1 promoted miRNA biogenesis more significantly in Huh7-MEKDD cells, with higher XPO5 phosphorylation, than in Huh7-CTL cells (Fig. 4F) , suggesting that Pin1-mediated and/or API-1-mediated miRNA biogenesis depended on XPO5 phosphorylation. Taken together, we demonstrated that Pin1 recognized and cis/trans isomerized serine-phosphorylated XPO5, altered the protein conformation of pXPO5, impaired the nucleus-tocytoplasm export of pre-miRNAs, and down-regulated mature miRNA biogenesis. Pin1 inhibition by API-1 increased biogenesis of anticancer miRNAs, leading to HCC suppression.
Pin1 INHIBITION SUPPRESSES TUMOR GROWTH IN MICE BY UP-REGULATING MATURE miRNA BIOGENESIS
To evaluate the antitumor activity of API-1 in mice, we firstly performed in silico "absorption, distribution, metabolism, excretion, and toxicity properties" descriptors and toxicity prediction (TOPKAT) calculations. The results indicated that API-1 was good in intestinal absorption and showed no or low toxicity in most toxicity prediction models (Supporting Table S3 ), showing acceptable druggability. The pharmacokinetic properties of API-1 were assessed with pharmacokinetic concentration-time curves and parameters (Supporting Fig. S5A and Table S4), which indicated that API-1 had a longer half-life and higher drug exposure 9 555 than juglone in mice. (28) In xenograft mice, API-1 suppressed SK-Hep-1 ( Fig. 5A; Supporting Fig. S5B , C) and Hep3B ( Fig. 5B; Supporting Fig. S5D,E) tumor growth. But API-1 was not sensitive to SMMC-7721 tumors ( Fig. 5C; Supporting Fig. S5F , G). Compared with SMMC-7721 cells, SK-Hep-1 and Hep3B cells had a higher level of XPO5 phosphorylation and Pin1 expression (Fig. 3B) . Therefore, these results demonstrated that the antitumor effect of API-1 is in a phosphorylated XPO5-dependent, and Pin1-dependent manner. This conclusion was further confirmed by using SK-Hep-1-CTL and shPin1 SK-Hep-1-shPin1 cells in a xenograft experiment ( Fig. 5D; Supporting Fig. S5H,I ). Moreover, API-1 suppression of tumor growth was dose-dependent (Fig. 5E ). Pin1 expression in tumors was not affected by API-1 (Supporting Fig. S5J ). In agreement with the preceding mechanistic results, mature miRNA biogenesis was increased upon API-1 injection (Fig. 5F ). In addition, API-1 showed no impact on the body weight of mice (Supporting Fig.  S5B,D,F) . The histopathology test revealed that API-1 had no remarkable toxicity to organs (Supporting Fig. S5K) . Moreover, the blood biochemistry of mice and immunohistochemical analysis of mice liver tissue (anti-RIP3, RIP3 is a biomarker of tissue necrosis) showed that API-1 administration would not induce liver damage and necrosis (Supporting Fig. S5L and Table S5 ). Importantly, API-1 had no cytotoxicity to normal hepatocytes (Supporting Fig. S5M ). Taken together, these data indicated that API-1 suppressed in vivo tumor growth by targeting Pin1 and modulating mature miRNA biogenesis.
Discussion
HCC incidence rates are increasing in many regions of the world. Unfortunately, most individuals diagnosed with HCC are at an advanced stage, (29) in which sorafenib is the only approved but less effective pharmacological therapy. (30) Therefore, a new type of therapy is currently in great demand. miRNAs are closely correlated with tumorigenesis and globally downregulated in many tumors, including HCC. (9, (31) (32) (33) miR-122, the most abundant and liver-specific tumor suppressor miRNA, is drastically reduced in HCC. (34, 35) Deletion of miR-122 increases the tumor incidence in mice, (36, 37) while injection of miR-122 mimic results in 50% growth suppression of HCC xenografts, (38) suggesting a potential miRNA-based therapy for HCC. (39) Recently, we revealed that Pin1 down-regulates miRNA biogenesis by alternating the conformation of pXPO5 and promotes HCC development, (15) indicating that enhancing miRNA biogenesis by inhibiting Pin1 is a promising strategy to treat HCC. In this study, we found that Pin1 inhibitor API-1 activated the biogenesis of anticancer miRNAs and suppressed in vitro and in vivo HCC cell growth (Figs. 3-5) , providing experimental data to Pin1-targeted chemotherapy for HCC and highlighting the therapeutic perspective of an miRNA-based approach for human cancers.
The general understanding of Pin1 in human cancer is that it promotes cancer occurrence and development by activating numerous oncogenic genes and proteins, including c-Myc, Mcl-1, and AKT. (40) It has been shown that c-Myc transcription is negatively regulated by miR-122 in liver (41) and that miR-29b decreased the Warburg effect in ovarian cancer by downregulating AKT expression (42) and induced myeloma cell apoptosis by targeting Mcl-1. (43) This work shows that Pin1 inhibition by API-1 increases the expression of miR-122 and miR-29b (Figs. 4E,F and 5F ), indicating that Pin1 may activate oncogenes or growthpromoting regulators through suppressing miRNA expression, which provides an alternative mechanism of Pin1-mediated cancer signaling and increases the understanding of Pin1 in cancer development. On the other hand, Farra et al. investigated whether Pin1 down-regulation induced G 1 -S block in native Huh7 cells. Pin1 inhibition may induce G 1 -S block by down-regulating the expression of cyclin D1, cyclin E, and cyclin A2. (44) However, native Huh7 cells display moderate Pin1 expression but lower pXPO5 level (Fig.  3B) and are insensitive to Pin1/pXPO5-mediated miRNA biogenesis. In this study, API-1 up-regulates miRNA biogenesis, such as miR-122 and let-7a (Fig.  4E,F) , and increases the S-phase cell number in SKHep-1 cells ( Fig. 3E; Supporting Fig. S3F ), which are sensitive to Pin1/pXPO5-mediated miRNA biogenesis. Both miR-122 and let-7a have the ability to induce cell cycle arrest by increasing cell number in S phase, (45, 46) providing a possible explanation for API-1-induced S-phase block in these cells.
API-1 potently and selectively inhibits Pin1 isomerase activity. To the best of our knowledge, apart from polypeptide-type Pin1 inhibitors, API-1 is the strongest small molecule-type Pin1 inhibitor, (40) with an IC50 value of 72.3 nM (Fig. 1E) . Meanwhile, API-1 shows inhibition of Pin1 over Pin4 (Fig. 1F) , another parvulin family of peptidyl-prolyl cis-trans isomerases, exhibiting improved selectivity characteristics over other Pin1 inhibitors, including juglone, PiB, epigallocatechin gallate, all-trans retinoic acid, and KPT-6566. (18, 19, 21, 47, 48) Structurally, Pin1 has a conserved sequence and a distinct three-dimensional structure for the PPIase domain. Flexible docking, molecular dynamic simulations, and site-directed mutations ( Fig.  2; Supporting Fig. S2 ) provided experimental proof to the structure complementation of PPIase domain and API-1, explaining why API-1 selectively inhibits Pin1 but not other peptidyl-prolyl cis-trans isomerases. Moreover, the structural biology of Pin1/API-1 cocrystal is under investigation to further describe the detailed binding mechanism. API-1 suppresses HCC cells in a Pin1-dependent and pXPO5-dependent manner. In the posttranscriptional regulation of miRNA biogenesis by Pin1/ XPO5/pre-miRNA axis, Pin1 function depends on the phosphorylation level of XPO5. Increased XPO5 phosphorylation facilitates the Pin1-mediated miRNA down-regulation in HCC. (15) However, with the inhibition of Pin1, XPO5 is active to export pre-miRNA from nucleus to cytoplasm, even though XPO5 is highly phosphorylated (Fig. 4) . Therefore, based on our data in Fig. 3 and Supporting Fig. S3 , it is rational to conclude that (1) the anticancer activity of API-1 in HCC primarily depends on Pin1 level (low Pin1 expression sharply decreases API-1 activity, no matter whether XPO5 is highly phosphorylated) and (2) in HCC cells with high level of Pin1, XPO5 phosphorylation is required to mediate API-1 function. Enhanced XPO5 phosphorylation potentiates the activity of API-1.
API-1 specifically locates to the PPIase domain, inhibits Pin1 isomerizing activity toward serinephosphorylated XPO5, restores the nucleus-tocytoplasm export of pre-miRNAs and pXPO5, and up-regulates miRNA biogenesis, leading to HCC suppression (Fig. 4) . This anticancer mechanism is distinct from those of reported Pin1 inhibitors. The small-molecule Pin1 inhibitors juglone, PiB, and phenyl imidazole reduce cyclin levels and block cell cycle progression in cancer cells. (47, 49, 50) All-trans retinoic acid induces Pin1 ablation and degrades the protein encoded by the fusion oncogene PML-RARA, thereby blocking multiple cancer pathways. (21) KPT-6566 covalently binds to Pin1 and induces Pin1 degradation and DNA damage in cancer cells. (48) Although it is undeniable that API-1 might affect these canonical mechanisms, our data demonstrate that the anticancer phenotype of API-1 is, at least in part, attributed to its property of modulating miRNA biogenesis. In basal conditions of ERK-activated HCC, XPO5 is phosphorylated by ERK and isomerized by Pin1, which makes XPO5 "inactive" to load premiRNAs and accomplish nucleus-tocytoplasm export. After API-1 treatment, API-1 inhibits Pin1 activity, keeping XPO5 "active" to recognize and export pre-miRNA to the cytoplasm, up-regulating mature miRNA biogenesis and suppressing HCC development. Abbreviation: GTP, guanosine triphosphate.
